Pharmacogenomics in pediatric acute lymphoblastic leukemia: Promises and limitations

Zeina N. Al-Mahayri, George P. Patrinos, Bassam R. Ali

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Despite the significant advances achieved in pediatric acute lymphocytic leukemia (ALL) treatment, adverse side effects of drugs remain a challenging issue. Numerous ALL pharmacogenomic studies have been conducted to elucidate the predisposing genetic factors for their development. Plausible pharmacogenomic data are available for the osteonecrosis associated with glucocorticoids, the neurotoxicity associated with vincristine and the cardiotoxicity related to anthracyclines. However, these data have not been fully translated into the clinic due to several limitations, most importantly the lack of reliable evidence. The most robust pharmacogenomics data are those for thiopurines and methotrexate use, with evidence-based preemptive testing recommendations for the former. Pharmacogenomics has a significant potential utility in pediatric ALL treatment regimens. In this review, gaps and limitations in this field are emphasized, which may provide a useful guide for future research design.

Original languageEnglish
Pages (from-to)687-699
Number of pages13
Issue number7
Publication statusPublished - May 2017


  • ALL
  • acute lymphocytic leukemia
  • adverse side effects
  • anthracyclines
  • asparaginase
  • chemotherapy glucocorticoids
  • methotrexate
  • pharmacogenomics
  • thiopurines
  • vincristine

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Pharmacogenomics in pediatric acute lymphoblastic leukemia: Promises and limitations'. Together they form a unique fingerprint.

Cite this